SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 19, 2011

IMAGINE MEDIA, LTD.

(Exact name of Registrant as specified in its charter)

Delaware	000-53316	26-0731818
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

3030 Old Ranch Parkway, Suite 350
Seal Beach, CA 90740

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (562) 280-0483

7750 N. Union Blvd., #201
Colorado Springs, CO 80920

(Former name or former address if changed since last report)

Item 2.01 Completion of Acquisition or Disposition of Assets

BACKGROUND AND ACQUISITION OF TRANSBIOTEC, INC.

The Company was formed in August 2007 to publish and distribute Image Magazine. Image Magazine was a monthly guide and entertainment source for the Denver, Colorado area. The Company generated only limited revenue and abandoned its business plan in January 2009.

On September 19, 2011 the Company acquired approximately 52% of the outstanding shares of TransBiotec, Inc., ("TBT") from TBT's directors, in exchange for 12,416,462 shares of the Company's common stock. TBT is a California Corporation. Prior to the acquisition the Company had 1,500,000 outstanding shares of common stock.

The Company plans to acquire the remaining outstanding shares of TBT at a later date in consideration for the issuance of 11,141,348 shares of the Company's common stock to the remaining TBT shareholders.

As a result of the acquisition, TBT's business is that of the Company, and, unless otherwise indicated, any references to the Company include the business and operations of TBT.

BUSINESS OF TRANSBIOTEC

TBT has developed and patented a preventative drunk driving system, named "SOBR" which is comprised of a blood alcohol detection system and ignition interlock device. The Company believes SOBR offers a unique solution to the national drunk driving problem.

SOBR can be ether retrofitted or built into the steering wheel, yoke or trim of any machine, including automobiles, busses, trucks, boats and aircraft. For example, when a driver of a vehicle touches a sensor, the senor detects vapors that emanate from the hands, and determines if there is ethanol alcohol content. This information is instantly translated into an engine "start" or "no-start" signal. If SOBR detects a Blood Alcohol Concentration ("BAC") that is above a preset limit, the system does not allow the vehicle to start. In addition, SOBR initiates random real-time tests while the vehicle is operating to ensure that the operator's BAC does not increase over the preset limit after the vehicle is started. If the system is tampered with while parked, the vehicle will not start. If tampered with while driving, alarms will activate. If a vehicle is equipped with a Global Positioning System, or Data Transmission Module, SOBR can alert fleet operators or others monitoring a vehicle of the detection of alcohol above legal limits.

The Company believes SOBR is the first product to the market of its kind. The detection sensor is specific to ethanol alcohol that is found in beer, wine and spirits and is calibrated to a specific operator which prevents other persons from testing instead of the operator. Furthermore, when SOBR is installed, the system is virtually unnoticeable, unlike breathalyzer ignition interlock systems.

Several major insurance companies which have expressed interest in SOBR since alcohol related accidents are a major factor in their loss ratios. If SOBR could reduce their claims costs they may entertain establishing discounts for its use.

SOBR requires approximately one hour to install in a vehicle. The control box is mounted under the dash in the interior of the vehicle. In new vehicles the sensor is installed as part of the steering wheel. In retrofits, the sensor is installed on the dashboard for easy access.

TBT believes that the cost to manufacture and install SOBR on a vehicle will be approximately $150-$250 less than existing breathalyzer systems.

SOBR requires a semi-annual recalibration much like current smog devices. The re-calibration is accomplished with a hand held device plugged into the control box and requires a trained technician approximately one hour to complete.

The Company plans to license the installation and re-calibration rights to the automotive service industry.

Marketing

The following are the primary target markets for SOBR:

Original Equipment Market. Original Equipment Manufacturers ("OEM") are the gate keepers for all new vehicle manufacturing. The Company will aggressively pursue the OEM market once final beta testing is completed. The Company will seek an experienced OEM partner to introduce SOBR to the new automotive market. If public awareness and consumer interest generate demand for alcohol sensing technology, auto manufacturers may begin installing SOBR as a factory installed option. An additional strategy for the Company is to market to international car manufacturers which may want to gain a market advantage over domestic auto manufacturers.

Retro Fit Market. The Company will enter this market thru a variety of sales channels including Zero Tolerance, teen driver, trucking, and airline. Additionally, the Company will seek to have included in any federal legislation a requirement that an ignition interlock system be retrofitted to all vehicles in the U.S. There is significant rational to enact this requirement. The highest percentage of drunken driving accidents and deaths occur in the young adult population, with older vehicles. The objective is to eliminate drunk driving accidents nationally, and the only viable option is to retro-fit every vehicle in the US over a set period of time.

Zero-Tolerance Market. Many companies have significant financial interest in eliminating drunk drivers from their operations. The Zero Tolerance applications include trucking companies, buses, trains, taxis, pilot screening and operating rooms at clinics and hospitals. In addition individuals may desire to monitor a family member's vehicle such as an automobile operated by a minor.

Mandated Market. The judicial mandated market monitors drivers convicted of alcohol-related offenses. However, existing models are clunky, large, unsightly and not driver specific. It is estimated that judicial mandated ignition interlocks probably generate less than $45 million in annual revenue. TBT will pursue this market with the goal of replacing the old, antiquated technology with SOBR. TBT will sell or license its system into the judicial mandated market through existing, state approved interlock providers on a wholesale basis.

Initially, the Company plans to market SOBR to:

o commercial transportation companies that operate tractor trailers, taxis, construction vehicles, boats, trains, aircraft and other vehicles,

- local, state and federal government agencies that operate fire trucks, police cars and public transportation systems, and

- individuals may desire to monitor a family member's vehicle, such as a vehicle operated by a minor.

The Company plans to establish a sales representative team and to advertise via direct mail, email, print, internet and social media avenues.

Manufacturing

The manufacture of all components of the SOBR, as well as component assembly, will be subcontracted to third parties. The final assembly, testing and calibration of the SOBR will be performed by the Company.

If and when orders for SOBR exceed approximately 3,000 units, the Company plans to transition the manufacturing and assembly processes offshore to contractors who have the ability to manufacture SOBR to the Company's specifications.

Competition

Currently, breathalyzer ignition interlocks are the only products on the market which can detect alcohol and lock the ignition system of a vehicle. There are several limitations inherent with their current design in that they are easily circumvented and are invasive in their appearance and use. At present, their market is limited to the mandated market.

The Company believes SOBR has the following advantages over current breathalyzers:

- High level of accuracy as ethanol alcohol is distinguished from other elements;
- The driver is the only one tested;
- Works during the entire operation of the vehicle without distracting the driver;
- The system is non-invasive;
- Easy retro fit installation;
- Unobtrusive in the vehicle;
- Difficult to circumvent.
- Possible opportunity for the consumer to obtain insurance discounts that could offset some costs of the system.

Although the Company's technology differs substantially from its competitors, the Company will compete with larger and more established breath alcohol ignition interlock providers that have been utilizing breathalyzer technology since approximately 1990.

The Company's main competitors will be National Interlock Systems, Inc., Lifesafer Interlock, Guardian Interlock Systems, Consumer Safety Technology, Smart Start, Inc., AAA Interlock and Drager.

Intellectual Property

SOBR is protected by three patents filed with the United States Patent and Trademark Office. Patent 6620108, which expires on December 26, 2021, pertains to the technology that identifies the vehicle's operator. Patent 7173536, which expires on August 28, 2024, pertains to the substance detection and alarm system. Patent 7377186, which expires on April 6, 2025, covers the interface system between the substance detection system and vehicle ignition system.

Government Regulation

At the present time, only the judicially mandated market is regulated. Devices sold into this market must be approved by state government agencies. Since the Company plans to enter this market last, the Company will not, initially, be subject to government regulation.

Ventura Agreement

On September 15, 2011 TBT entered into an agreement with Ventura LLC ("Ventura"). Pursuant to the agreement, Ventura will receive the following shares of the Company's common stock:

- 842,544 shares for assisting with the Company's acquisition of its 52% interest in TBT;

- o 842,544 shares when $250,000 is raised from the sale of 100,000 shares of the common stock of TBT at $2.50 per share. All shares sold in this offering will be exchanged for shares of the common stock of the Company on the basis of one TBT share for 7.726 shares of the Company's common stock;

- o 842,544 for shares sold by the Company prior to March 31, 2012 to investors introduced to the Company by Ventura, provided at least $250,000 is raised from such investors prior to March 31, 2012;

- o 842,544 shares for shares sold by the Company prior to March 31, 2012 to investors introduced to the Company by Ventura, provided an additional $500,000 is raised from such investors prior to March 31, 2012; and

- o 842,544 shares for shares sold by the Company prior to March 31, 2012 to investors introduced to the Company by Ventura, provided an additional $500,000 is raised from such investors prior to March 31, 2012.

If the Company raises at least $1,250,000 from investors introduced to the Company by Ventura, the Company will grant Ventura the exclusive rights to Denver, Douglas and Jefferson counties, Colorado for installations and recalibrations of the SOBR system.

Convertible Notes

As of June 30, 2011, TBT owed Sam Satyanarayana, a director of TBT and a future director of the Company, $154,774, which amount is evidenced by a promissory note. The note is unsecured, bears interest at 8% per year and is due July 27, 2012. The principal amount of the note (plus accrued interest of $241,951 as of June 30, 2011) is convertible into shares of TBT's common stock at a conversion rate of $2.50 per share.

As of June 30, 2011, TBT owed a shareholder of TBT $150,000, which amount is evidenced by a promissory note. The note is unsecured, bears interest at 22.1% per year and is due on December 15, 2013. The principal amount of the note (plus accrued interest of $266,025 as of June 30, 2011) is convertible into shares of TBT's common stock at a conversion rate of $2.50 per share.

As of June 30, 2011, TBT owed the same shareholder referred to above $240,000, which amount is evidenced by a promissory note. The note is unsecured, bears interest at 67% per year, and was due on May 28, 2009. The principal amount of the note (plus accrued interest of $937,465 as of June 30, 2011) is convertible into shares of TBT's common stock at a conversion rate of $2.50 per share.

Legal Proceedings

On December 6, 2006 Orange County Valet and Security Patrol, Inc. filed a suit against TBT in Orange County California State Superior Court for Breach of Contract in the amount of $9,720.00. As of the date of this report the lawsuit remained pending, however, the plaintiff has not taken any further action in this case.

On November 14, 2005, Fashion Furniture Rental, Inc. filed a lawsuit against TBT in Orange County California State Superior Court for Breach of Contract in the amount of $60,541.76. The rental furniture has been returned and, although, as of the date of this report, the lawsuit remained pending, the plaintiff has not taken any further action in this case.

General

The Company's offices, consisting of approximately 1000 square feet, are located at 3030 Old Ranch Parkway, Suite 350, Seal Beach, CA 90740. The Company sub-leases this space at a rate of $1700 per month. The Company uses this space for its executive offices.

The Company's website is www.transbiotec.com.

The Company's telephone number is (562) 280-0483.

As of August 31, 2011 the Company employed five persons on a full time basis and two persons on a part-time basis.

RISK FACTORS

Potential investors should consider the following risks before investing in the Company's common stock.

The Company is in the development stage and may never be profitable. As of the date of this report the Company has not generated any revenue. The Company has never earned a profit and expects to incur losses during the foreseeable future and may never be profitable.

The failure of the Company to obtain capital may significantly restrict the Company's proposed operations. The Company needs additional capital to fund operating losses and to expand business.

The Company does not know what the terms of any future capital raising may be but any future sale of equity securities would dilute the ownership of existing stockholders. The failure to obtain the capital will result in a slower implementation of the Company's business plan. There can be no assurance that the Company will be able to obtain any capital which is needed.

The Company will need to obtain additional financing until it is able to earn a profit. As a result of the Company's short operating history it is difficult for potential investors to evaluate the Company's business. There can be no assurance that the Company can implement its business plan or that it will be profitable.

The Company's operations are dependent upon the continued services of its officers. The loss of any of any of the Company's officers, whether as a result of death, disability or otherwise, may have a material adverse effect upon the Company's business.

MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION

The following discussion:

- summarizes the Company's plan of operation; and
- analyzes TBT's financial condition and the results of its operations for the year ended December 31, 2010 and the six months ended June 30, 2011.

This discussion and analysis should be read in conjunction with TBT's financial statements included as an exhibit to this report.

Plan of Operation and Capital Requirements

The Company's plan of operations is as follows:

Activity	Projected Completion Date	Estimated Cost
Develop relationship with initial customers willing to work with Company in refining SOBR. Will discount price for units sold to customers who partner with Company in this phase. Identify add-on features that may appeal to customers. Complete design of printed circuit boards and injection molding tools. Sales target of 500 units.	October 2011	$160,000
Outsource manufacturing, packaging and shipping. Complete joint venture agreement with GPS partner. Develop add-on features such as cameras, GPS and radio interfaces, and a fingerprint reader which would allow the SOBR to determine the driver's identity and blood alcohol content at the same time. Improve production capability to 1,000 units per month.	January 2012	$185,000
Improve manufacturing capability to 10,000 units per month	July 2012	$370,000

The Company will maintain its research and development efforts with a goal of continuously improving the SOBR.

The Company does not have any firm commitments from any third parties to provide it with any additional capital.

TBT's sources and (uses) of funds for the years ended December 31, 2010 and 2009 and the six months ended June 30, 2011 and 2010 are shown below:

	Year ended December 31,		Six Months ended June 30,	
	2009	2010	2010	2011
Net cash provided by (used for) operations	$(384,247)	$(94,752)	$(15,159)	$(181,119)
Loans, net of loan repayments	234,155	(2,757)	2,672	(3,655)
Sale of stock	67,500	127,500	12,500	198,500
Cash on hand at the beginning of the period	82,565	-	-	-

The following table summarizes the Company's and TBT's combined contractual obligations as of June 30, 2011:

	2011	2012	2013	Total
The notes payable, together with accrued interest	$1,0175,212	--	--	$1,0175,212

The Company does not have any off-balance sheet arrangements that have or are reasonable likely to have a current or future material effect on its financial condition, changes in financial condition, results of operations, liquidity or capital resources.

Other than as disclosed above, the Company does not know of any trends, demands, commitments, events or uncertainties that will result in, or that reasonably likely to result in, the Company's liquidity increasing or decreasing in any material way.

Other than as disclosed above, the Company does not know of any significant changes in its expected sources and uses of cash.

Results of Operations

The Company was formed in August 2007 and generated only limited revenue before it effectively ceased operations in January 2009. TBT was formed in July 2004 and has never generated any revenue.

Material changes in TBT's Statement of Operations for the year ended December 31, 2010 as compared to the same period in the prior year are discussed below:

Item	Increase (I) or Decrease (D)	Reason
General and Administrative Expenses	D	The Company reduced its level of operations during 2010 to conserve cash

There were no material changes in TBT's Statement of Operations for the six months ended June 30, 2011 as compared to the same period in the prior year.

MANAGEMENT

Following the acquisition of the Company's 52% interest in TBT, Greg Bloom and Harlan Munn resigned as officers of the Company and the following persons were appointed as the new management of the Company.

Name	Age	Position
Charles Bennington	67	President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer and Director
Ronald Williams	66	Chief Technology Officer
Nicholas Limer	66	Secretary and a Director

The Company's directors serve until the next annual meeting of the Company's shareholders and until their successors have been duly elected and qualified. The Company's officers serve at the discretion of the Company's directors.

Information concerning the Company's new officers and directors follows:

Charles Bennington has been TBT's President and its Principal Executive, Financial and Accounting Officer since December 2006. Between May 2005 and December 2006 Mr. Bennington was TBT's Chief Operating Officer. Mr. Bennington has been a director of TBT since April 2005. Mr. Bennington holds a Degree in Finance and Banking from the University of Miami, Ohio.

Ronald Williams has been TBT's Chief Technology Officer since October 28, 2005. Mr. Williams has been a director of TBT since June 3, 2010. Since 1993, Mr. Williams has owned and operated a mixed fruit tree orchard in Fallbrook, California. Since 1972, Mr. Williams has worked as an aerospace engineer and since 2005, Mr. Williams has been employed as a Principal Engineer for the Aerospace Corporation in El Segundo, California. Mr. Williams holds a Bachelor of Science Degree in physics from the University of California at Los Angeles and has performed graduate studies in mechanical and material engineering at Cal State Northridge.

Nicholas Limer has been a director of TBT since April 8, 2005. Since 1998 Mr. Limer has acquired, developed and managed self storage properties in Southern California and Hawaii. Mr. Limer's the Managing Member of McKenna's On The Bay restaurant in Long Beach. Mr. Limer holds a Bachelor of Science Degree in Aeronautical Engineering from the Ply Technical Institution of Brooklyn, a Masters of Science Degree in Engineering from California State University, Long Beach and a Masters of Business Administration Degree from California State University, Long Beach.

Ten days after the Company's compliance with Rule 14f-1 of the Securities and Exchange Commission, Gregory Bloom and Harlan Munn will resign as directors of the Company and Ronald Williams, Sam Satyanarayana and Devadatt Mishal will be appointed directors of the Company.

Sam Satyanarayana (age 71) has been a director of TBT since June 3, 2010. Between October 2004 and December 2006 Mr. Satyanarayana was TBT's Chief Executive Officer and President. Since 1990, Mr. Satyanarayana has been the Chief Executive Officer of Autosense International which designs, manufactures and markets breath alcohol ignition devices. Mr. Satyanarayana holds a Bachelor of Science Degree in Computer Engineering from the University of Mysore, India, a Masters of Science in Engineering from Oklahoma State University and a Masters of Business Administration from the University of Rochester.

Devadatt Mishal (age 63) has been a director of TBT since June 3, 2010. Dr. Mishal has been practicing as an Obstetrician and Gynecologist since March 1982 in Downey, California. Dr. Mishal received his medical degree from Lokmanya Tilak Municipal Medical College and Maharashtra University of Health Sciences in Mumbai, India.

Following their appointment, Sam Satyanarayana and Devadatt Mishal will be independent directors, as that term is defined in Section 803 of the listing standards of the NYSE Amex. No director is a "financial expert" as that term is defined in the regulations of the Securities and Exchange Commission.

The Company believes all of its directors are qualified to act as such due to their longstanding relationship with the Company or TBT.

The Company does not have a compensation committee. The Company's Board of Directors serves as its Audit Committee.

The Company has not adopted a Code of Ethics applicable to its principal executive, financial, and accounting officers and persons performing similar functions. The Company does not believe a Code of Ethics is necessary at this time since the Company only has three officers.

The following table shows the compensation paid or accrued during the three years ended December 31, 2010 to the executive officers of the Company.

<TABLE>
<S> <C> <C> <C> <C> <C> <C> <C>

Name and Principal Position	Fiscal Year	Salary (1)	Bonus (2)	Stock Awards (3)	Option Awards (4)	All Other Annual Compensation (5)	Total
Charles Bennington	2010	$120,000	-	-	-	-	$120,000
President and Chief Executive Officer	2009	$120,000	-	-	-	-	$120,000

Ronald Williams	2010	-	-	-	-	-	-
Chief Technology	2009	-	-	-	-	-	-
Officer							
	-						
Nicholas Limer	2010	-	-	-	-	-	-
Secretary and	2009	-	-	-	-	-	-
Director							

</TABLE>

(1) The dollar value of base salary (cash and non-cash) earned.
(2) The dollar value of bonus (cash and non-cash) earned.
(3) During the periods covered by the table, the value of the Company's shares issued as compensation for services to the persons listed in the table.
(4) The value of all stock options granted during the periods covered by the table.
(5) All other compensation received that the Company could not properly report in any other column of the table.

In May 2011 the Company entered into an employment agreement with Mr. Bennington which expires on the earlier of December 31, 2016 or Mr. Bennington's death. The employment agreement provides that the Company will pay Mr. Bennington a salary of $120,000 during the first year of the agreement, $156,000 during the second year of the agreement, $172,000 during the third year of the

agreement, $190,000 during the fourth year of the agreement and $208,000 during the fifth year of the agreement. In addition the agreement allows Mr. Bennington to participate in all employee benefit plans generally available to the Company's employees.

Long-Term Incentive Plans. The Company does not provide its officers or employees with pension, stock appreciation rights, long-term incentive or other plans and has no intention of implementing any of these plans for the foreseeable future.

Employee Pension, Profit Sharing or other Retirement Plans. The Company does not have a defined benefit, pension plan, profit sharing or other retirement plan, although it may adopt one or more of such plans in the future.

Compensation of Directors. The Company's directors did not receive any compensation for their services as directors during the fiscal year ended December 31, 2010.

Stock Option and Bonus Plans

The Company has not adopted any stock option or stock bonus plans.

The following shows the amounts the Company expects to pay to its officers during the twelve months ending August 31, 2012 and the amount of time these persons expect to devote to the Company.

Name	Position	Projected Compensation	% of time to be devoted to Company's business
Charles Bennington	Chief Executive Officer	$120,000	100%
Ronald Williams	Chief Technology Officer	$ 42,000	25%
Nicholas Limer	Secretary	$ 12,000	25%

PRINCIPAL SHAREHOLDERS

The following table shows the ownership, following the acquisition of the Company's 52% interest in TBT, of those persons owning beneficially 5% or more of the Company's common stock and the number and percentage of outstanding shares owned by each of the Company's directors and officers and by all officers and directors as a group, including the directors to be appointed after the Company's compliance with Rule 14f-1 of the Securities and Exchange Commission. Unless otherwise indicated, each owner has sole voting and investment power over their shares of common stock.

Name and Address	Shares Owned	% of outstanding shares owned after acquisition of 52% interest in TBT	% of outstanding shares owned after acquisition of 100% interest in TBT
Charles Bennington 3030 Old Ranch Parkway, Ste 350	1,004,422	7.26	4.0

Seal Beach, CA 90740			

Ronald Williams 35569 Rice Canyon Road Fallbrook CA 92028	--	--	--
Nicholas Limer 3030 Old Ranch Parkway, Ste 350 Seal Beach, CA 90740	5,466,720	39.54	21.9
Sam Satyanarayana 683 E. Brokaw Rd San Jose, Ca 95112	5,636,267	40.76	22.6
Gregory A. Bloom 1543 10th St., #3 Santa Monica, CA 90401	40,000	*	*
Harlan Munn 5758 Singletree Lane Parker, Colorado 80134 Downey, CA 90241	39,350	*	*
All officers and directors as a group (6 persons)	12,186,759	89.3	49.7

(1) 3,245,000 of these shares are held of record by relatives of Mr. Limer. However Mr. Limer is deemed to be the beneficial owner of these shares.

* Less than 1%

DESCRIPTION OF SECURITIES

Common Stock

The Company is authorized to issue 100,000,000 shares of common stock. Holders of the Company's common stock are each entitled to cast one vote for each share held of record on all matters presented to the shareholders. Cumulative voting is not allowed; hence, the holders of a majority of the Company's outstanding common shares can elect all directors.

Holders of the Company's common stock are entitled to receive such dividends as may be declared by the Company's Board of Directors out of funds legally available and, in the event of liquidation, to share pro rata in any distribution of the Company's assets after payment of liabilities. The Company's Board of Directors is not obligated to declare a dividend. It is not anticipated that dividends will be paid in the foreseeable future.

Holders of the Company's common stock do not have preemptive rights to subscribe to additional shares if issued. There are no conversions, redemption, sinking fund or similar provisions regarding the common stock. All outstanding shares of common stock are fully paid and non-assessable.

Preferred Stock

The Company is authorized to issue 25,000,000 shares of preferred stock. Shares of preferred stock may be issued from time to time in one or more series as may be determined by the Company's Board of Directors. The voting powers and preferences, the relative rights of each such series and the qualifications, limitations and restrictions of each series will be established by the Board of Directors. The Company's directors may issue preferred stock with multiple votes per share and dividend rights which would have priority over any dividends paid with respect to the holders of the Company's common stock. The issuance of preferred stock with these rights may make the removal of management difficult, even if the removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in transactions such as mergers or tender offers if these transactions are not favored by the Company's management. As of August 25, 2010, the Company had not issued any shares of preferred stock.

Transfer Agent

Corporate Stock Transfer
3200 Cherry Creek Drive South, Suite 430

Denver, Colorado 80209
Phone: 303-282-4800
Fax: 303-282-5800

INDEMNIFICATION

The Company's Bylaws authorize indemnification of a director, officer, employee or agent against expenses incurred by him in connection with any action, suit, or proceeding to which he is named a party by reason of his having acted or served in such capacity, except for liabilities arising from his own misconduct or negligence in performance of his duty. In addition, even a director, officer, employee, or agent found liable for misconduct or negligence in the performance of his duty may obtain such indemnification if, in view of all the circumstances in the case, a court of competent jurisdiction determines such person is fairly and reasonably entitled to indemnification. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to the Company's directors, officers, or controlling persons pursuant to these provisions, the Company has been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

Item 3.02 Unregistered Sales of Equity Securities

See Item 2.01 of this report. The shares issued in connection with the acquisition of TBT were restricted securities, as that term is defined in Rule 144 of the Securities and Exchange Commission. The Company relied upon the exemption provided by Section 4(2) of the Securities Act of 1933 with respect to the issuance of these shares. The persons who acquired these shares were all provided with information concerning the Company prior to the acquisition of their shares. The certificates representing the shares will bear legends stating that the shares may not be offered, sold or transferred other than pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to an applicable exemption from registration. No commissions were paid in connection with this transaction.

Item 5.01 Changes in Control of Registrant

See Item 2.01 of this report.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

See Item 2.01 of this report.

Item 5.06 Change in Shell Company Status

See Item 2.01 of this report.

Item 9.01 Financial Statements and Exhibits

Financial Statements of TransBioTec, Inc.

Exhibit	Description
10.3	Agreement to Exchange Securities (incorporated by reference to the same exhibit filed on August 18, 2011 with the Company's report on Form 8-K).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 19, 2011

IMAGINE MEDIA, LTD.

By: /s/ Charles Bennington

Charles Bennington, Chief Executive Officer

TRANSBIOTEC, INC.
(A Development Stage Company)

FINANCIAL STATEMENTS

December 31, 2009 and 2010, & June 30, 2011 (Unaudited)

TRANSBIOTEC, INC.
(A Development Stage Company)
Financial Statements

TABLE OF CONTENTS

RONALD R. CHADWICK, P.C.
Certified Public Accountant
2851 South Parker Road, Suite 720
Aurora, Colorado 80014
Telephone (303)306-1967
Fax (303)306-1944

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors
TransBioTec, Inc.
Seal Beach, California

I have audited the accompanying balance sheets of TransBioTec, Inc. (a development stage company) as of December 31, 2009 and 2010 and the related statements of operations, stockholders' equity and cash flows for the years then ended, and for the period from July 19, 2004 (inception) through December 31, 2010. These financial statements are the responsibility of the Company's management. My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of TransBioTec, Inc. as of December 31, 2009 and 2010, and the results of its operations and its cash flows for the years then ended, and for the period from July 19, 2004 (inception) through December 31, 2010 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 7 to the financial statements the Company has suffered recurring losses from operations and has a working capital deficit and stockholders' equity deficit that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 7. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Aurora, Colorado /s/ Ronald R. Chadwick, P.C.
August 17, 2011 RONALD R. CHADWICK, P.C.

TransBioTec,
Inc.
(A Development Stage Company)
BALANCE SHEETS

<TABLE>
<S> <C> <C> <C>

	Dec. 31, 2009	Dec. 31, 2010	June 30, 2011 (Unaudited)
ASSETS			
Current assets			
Cash	$ 704	$ 30,695	$ 44,421
Total current assets	704	30,695	44,421
Fixed assets - net	9,422	2,043	1,273
Total Assets	10,126	32,738	45,694
LIABILITIES & STOCKHOLDERS' EQUITY			
Current liabilities			
Accounts payable	$ 294,793	$ 279,840	$ 74,965
Accrued interest payable	260,071	508,180	516,678
Notes payable - current - related parties	577,256	594,966	558,534
Notes payable - current	4,657	-	-
Related party payables	361,565	130,565	157,827
Other payables	97,464	97,464	97,473
Total current liabilties	1,595,806	1,611,015	1,405,477
Notes payable - related parties	153,879	153,879	-
Total Liabilities	1,749,685	1,764,894	1,405,477
Stockholders' Equity			
Common stock, $.01 par value; 100,000,000 shares authorized;2,961,000 shares issued and 2,161,000 outstanding (2009), 3,117,000 shares issued and 2,342,000 outstanding (2010), & 3,475,544 shares issued and 2,779,544 outstanding (2011)	29,610	31,170	34,755
Additional paid in capital	7,602,009	8,098,398	8,705,779
Treasury stock at cost; 800,000 (2009), 775,000 (2010) & 696,000 (2011) common shares	(250,000)	(242,187)	(217,499)
Deficit accumulated during the development stage	(9,121,178)	(9,619,537)	(9,882,818)
Total Stockholders' Equity	(1,739,559)	(1,732,156)	(1,359,783)
Total Liabilities and Stockholders' Equity	$ 10,126	$ 32,738	$ 45,694

</TABLE>

The accompanying notes are an integral part of the financial statements.

TransBioTec, Inc.

(A Development Stage Company)
STATEMENTS OF OPERATIONS

<TABLE>
<S> <C> <C> <C> <C> <C>
<C>

	Year Ended Dec. 31, 2009	Year Ended Dec. 31, 2010	Six Months Ended June 30, 2010 (Unaudited)	Six Months Ended June 30, 2011 (Unaudited)	Period From July 19, 2004 (Inception) To Dec. 31, 2010	Period From July 19, 2004 (Inception) To June 30, 2011 (Unaudited)
Revenues	$ -	$ -	$ -	$ -	$ -	$ -
	-	-	-	-	-	-
Operating expenses:						
Amortization & depreciation	10,140	7,379	3,690	770	74,832	75,602
General and administrative	790,323	242,383	159,595	150,062	9,044,362	9,194,424
	800,463	249,762	163,285	150,832	9,119,194	9,270,026
Gain (loss) from operations	(800,463)	(249,762)	(163,285)	(150,832)	(9,119,194)	(9,270,026)
Other income (expense):						
Interest expense	(208,001)	(248,597)	(124,300)	(112,449)	(500,343)	(612,792)
Income (loss) before provision for income taxes	(1,008,464)	(498,359)	(287,585)	(263,281)	(9,619,537)	(9,882,818)
Provision for income tax	-	-	-	-	-	-
Net income (loss)	$ (1,008,464)	$ (498,359)	$ (287,585)	$ (263,281)	$(9,619,537)	$ (9,882,818)
Net income (loss) per share (Basic and fully diluted)	$ (0.48)	$ (0.23)	$ (0.13)	$ (0.10)		
Weighted average number of common shares outstanding	$ 2,109,150	$ 2,184,000	$ 2,166,000	$ 2,618,863		

</TABLE>

The accompanying notes are an integral part of the financial statements.

TransBioTec, Inc.
(A Development Stage Company)
STATEMENTS OF STOCKHOLDERS' EQUITY

<TABLE>
<S> <C> <C> <C> <C> <C> <C>

	Common Stock Shares	Amount ($.01 Par)	Additional Paid in Capital	Treasury Stock	Deficit Accumulated During The Development Stage	Stockholders' Equity
Balances at December 31, 2008	2,865,200	$ 28,652	$ 7,483,467	$ (250,000)	$ (8,112,714)	$ (850,595)
Option exercise	50,000	500	4,500			5,000
Sales of common stock	25,000	250	62,250			62,500
Stock issued for note conversion	20,800	208	51,792			52,000
Net income (loss) for the year					(1,008,464)	(1,008,464)
Balances at December 31, 2009	2,961,000	$ 29,610	$ 7,602,009	$ (250,000)	$ (9,121,178)	$ (1,739,559)
Sales of common stock (26,000 shares newly issued and 25,000 shares sold out of treasury)	26,000	260	119,427	7,813		127,500
Stock issued for debt	130,000	1,300	323,700			325,000
Option issuances			53,262			53,262
Net income (loss) for the year					(498,359)	(498,359)
Balances at December 31, 2010	3,117,000	$ 31,170	$ 8,098,398	$ (242,187)	$ (9,619,537)	$ (1,732,156)
Option exercise	10,000	100	900			1,000
Sales of common stock (79,000 shares sold out of treasury)	-	-	172,812	24,688		197,500
Stock issued for note conversion	288,544	2,885	287,159			290,044
Stock issued for debt	60,000	600	146,510			147,110
Net income (loss) for the period					(263,281)	(263,281)
Balance at June 30, 2011 - Unaudited	3,475,544	$ 34,755	$ 8,705,779	$ (217,499)	$ (9,882,818)	

$ (1,359,783)

============= ============== =============== ============= ============== =============

</TABLE>

The accompanying notes are an integral part of the financial statements.

TransBioTec, Inc.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS

<TABLE>

	Year Ended Dec. 31, 2009	Year Ended Dec. 31, 2010	Six Months Ended June 30, 2010 (Unaudited)	Six Months Ended June 30, 2011 (Unaudited)	Period From July 19, 2004 (Inception) To Dec. 31, 2010	Period From July 19, 2004 (Inception) To June 30, 2011 (Unaudited)
Cash Flows From Operating Activities:						
Net income (loss)	$ (1,008,464)	$ (498,359)	$ (287,585)	$ (263,281)	$ (9,619,537)	$ (9,882,818)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:						
Amortization & depreciation	10,140	7,379	3,690	770	74,832	75,602
Compensatory equity issuances	-	53,262	53,262	-	6,339,317	6,339,317
Asset write offs	37,513	-	-	-	37,513	37,513
Other assets	283	-	-	-	-	-
Accrued payables	536,281	342,966	215,474	81,392	1,321,346	1,402,738
Note pay. benefical conversion expense		-	-	-	203,564	203,564
Original issue discount - interest expense	40,000	-	-	-	40,000	40,000
Net cash provided by (used for) operating activities	(384,247)	(94,752)	(15,159)	(181,119)	(1,602,965)	(1,784,084)
Fixed asset purchases	-	-	-	-	(76,875)	(76,875)
Net cash provided by (used for) investing activities	-	-	-	-	(76,875)	(76,875)

</TABLE>

(Continued On Following Page)

The accompanying notes are an integral part of the financial statements.

TransBioTec, Inc.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS

(Continued From Previous Page)

<TABLE>
<S> <C> <C> <C> <C> <C> <C>

	Year Ended Dec. 31, 2009	Year Ended Dec. 31, 2010	Six Months Ended June 30, 2010 (Unaudited)	Six Months Ended June 30, 2011 (Unaudited)	Period From July 19, 2004 (Inception) To Dec. 31, 2010	Period From July 19, 2004 (Inception) To June 30, 2011 (Unaudited)
Cash Flows From Financing Activities:						
Notes & loans payable - borrowings	253,651	5,000	5,000	2,845	770,261	773,106
Notes & loans payable - payments	(19,469)	(7,757)	(2,328)	(6,500)	(27,226)	(33,726)
Repurchase of treasury stock	-	-	-	-	(250,000)	(250,000)
Equity issuances	67,500	127,500	12,500	198,500	1,217,500	1,416,000
Net cash provided by (used for) financing activities	301,682	124,743	15,172	194,845	1,710,535	1,905,380
Net Increase (Decrease) In Cash	(82,565)	29,991	13	13,726	30,695	44,421
Cash At The Beginning Of The Period	83,269	704	704	30,695	-	-
Cash At The End Of The Period	$ 704	$ 30,695	$ 717	$ 44,421	$ 30,695	$ 44,421
Schedule Of Non-Cash Investing And Financing Activities						
Compensatory equity issuances	$ -	$ 53,262	$ -	$ -	$ 6,339,317	$ 6,339,317
Debt converted to capital	$ 52,000	$ 325,000	$ -	$ 437,154	$ 377,000	$ 814,154
Supplemental Disclosure						
Cash paid for interest	$ 544	$ 488	$ 244	$ -	$ 6,672	$ 6,672
Cash paid for income taxes	$ -	$ -	$ -	$ -	$ -	$ -

</TABLE>

The accompanying notes are an integral part of the financial statements.

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

TransBioTec, Inc. (the "Company") was incorporated in the State of California on July 19, 2004. The Company has developed and plans to market and sell a non-invasive alcohol sensing system which includes an ignition interlock. The Company is currently considered to be in the development stage, and has not generated revenues from its activities.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts receivable

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At December 31, 2009 and 2010, and June 30, 2011 the Company had no balance in accounts receivable or the allowance for doubtful accounts.

Property and equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Revenue recognition

Revenue is recognized on an accrual basis as earned under contract terms. The Company has had no revenues to date

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)

Advertising costs

Advertising costs are expensed as incurred. The Company recorded no material advertising costs in 2009 or 2010, or for the six months ended June 30, 2011.

Income tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net income (loss) per share

The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.

Financial Instruments

The carrying value of the Company's financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that may suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Products and services, geographic areas and major customers

The Company is currently in the developmental stage and has no revenue.

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)

Stock based compensation

The Company accounts for employee and non-employee stock awards under ASC 718, whereby equity instruments issued to employees for services are recorded based on the fair value of the instrument issued and those issued to non-employees are recorded based on the fair value of the consideration received or the fair value of the equity instrument, whichever is more reliably measurable.

NOTE 2. RELATED PARTY TRANSACTIONS

At year end 2009 and 2010, and June 30, 2011 the Company had payables due to officers for accrued compensation of $361,565, $130,565, and $157,827.

In 2009 a related party shareholder converted $52,000 in note principal and interest into 20,800 common shares. In 2010 an officer converted $325,000 in compensation owed him into 130,000 common shares. During the six months ended June 30, 2011 related party shareholders converted $290,044 in note principal and interest into 288,544 common shares.

NOTE 3. FIXED ASSETS

Fixed asset values recorded at cost are as follows:

	December 31, 2009	December 31, 2010	(Unaudited) March 31, 2011
Automobile	$ 33,383	$ 33,383	$ 33,383
Office and Lab Equipment	31,896	31,896	31,896
Furniture and fixtures	11,596	11,596	11,596
	76,875	76,875	76,875
Less accumulated depreciation	(67,453)	(74,832)	(75,602)
Total	$ 9,422	$ 2,043	$ 1,273

TRANSBIOTEC, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
December 31, 2009 and 2010, & June 30, 2011 (Unaudited)

NOTE 3. FIXED ASSETS (cont'd)

Depreciation expense in 2009 and 2010, and for the six months ended June 30, 2011 was $10,140, $7,379 and $770 respectively.

NOTE 4. NOTES PAYABLE

	December 31, 2009	December 31, 2010	(Unaudited) June 30, 2011
Note payable to related party, unsecured, due 8/3/2012, interest rate 0%	$ 1,950	$ 1,950	$ 1,950
Note payable to related party, unsecured, due 9/17/2008, convertible at holder's option at $1 per share, interest rate 10% plus agreed upon amounts	$187,256	$184,156	$ 0
Note payable to related party, unsecured, due 12/15/2013, monthly interest due, convertible at holder's option at $2.50 per share, interest rate 22.1%	$150,000	$150,000	$150,000
Note payable to related party, unsecured, due 05/28/2009, convertible at holder's option at $2.50 per share, original issue discount of 20%, with interest at $444 per day after due date	$240,000	$240,000	$240,000
Note payable to related party, unsecured, due 07/27/2012, convertible at holder's option at $2.50 per share, interest rate 8%	$151,929	$151,929	$154,774

NOTE 4. NOTES PAYABLE (cont'd)

	December 31, 2009	December 31, 2010	(Unaudited) June 30, 2011
Notes payable to related parties, unsecured, due 01/29/2011, convertible at holder's option at $2.50 per share, interest rate 9%	$ -	$ 5,000	$ -
Notes payable to related parties, unsecured, due 12/31/2012, interest rate 0%	$ -	$ 15,810	$ 11,810
Note payable to Ford Motor Credit, secured, payment $584.25 per month	$ 4,657	$ -	$ -
	$735,792	$748,845	$558,534
Less current portion	(581,913)	(594,966)	(558,534)

Long-term portion	$153,879	$153,879	$ 0
	========	========	========

Required principal payments from December 31, 2010 forward are as follows:

2011	$ 581,913
2012	153,879

	$ 735,792
	===========

Interest expense under notes payable in 2009 and 2010, and for the six months ended June 30, 2011 was $206,078, $238,851, and $107,575.

NOTE 5. INCOME TAXES

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

At December 31, 2009 and 2010 the Company had net operating loss carryforwards of approximately $604,000 and $1,045,000 respectively, which begin to expire in 2027. The deferred tax asset of at each date of $120,000 and $209,000 created by the net operating losses has been offset by a 100% valuation allowance. The change in the valuation allowance in 2009 and 2010 was approximately $21,000 and $89,000.

NOTE 6. STOCK OPTIONS

The Company accounts for employee and non-employee stock options under ASC 718, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares.

The Company's stock option activity is described below.

Non-employee stock options

At the beginning of 2009 the Company had 60,000 non-employee stock options outstanding, allowing the holder to purchase one share of common stock per option, exercisable at $0.10 per share, with terms expiring from 2011 - 2013. During the year 50,000 options were exercised, and no options expired, leaving a 2009 year end outstanding balance of 10,000 non-employee stock options expiring in December 2011.

During 2010 the Company granted 22,500 options for services, allowing the holder to purchase one share of common stock per option, with 22,500 options exercisable immediately at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015. During 2010 no options were exercised, and no options expired, leaving a 2010 year end outstanding balance of 32,500 non-employee stock options. The fair value of the 22,500 options granted in 2010 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 1.08% - 2.67%, dividend yield of 0%, expected lives of 2 - 5 years, volatility of 100%. The Company incurred and recorded compensation expense under these stock option grants of $53,262 in 2010.

NOTE 6. STOCK OPTIONS (cont'd)

During the six months ended June 30, 2011 10,000 options were exercised, and no options expired, leaving a June 30, 2011 outstanding balance of 22,500 non-employee stock options, exercisable at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015.

Employee stock options

The Company had no outstanding employee stock options in 2009 or 2010, or during the six months ended June 30, 2011.

NOTE 7. GOING CONCERN

The Company has suffered recurring losses from operations and has a working capital deficit and stockholders' deficit, and in all likelihood will be required to make significant future expenditures in connection with continuing marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or others. By doing so, the Company hopes to generate revenues from sales of its alcohol sensing and ignition lock systems. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.